<DOC>
	<DOCNO>NCT02819284</DOCNO>
	<brief_summary>The primary purpose study determine efficacy safety KPI-121 0.25 % ophthalmic suspension compare vehicle ( placebo ) subject documented clinical diagnosis dry eye disease . The product study 14 day , 1-2 drop instill eye four time daily ( QID ) .</brief_summary>
	<brief_title>Safety Efficacy KPI-121 Compared Placebo Subjects With Dry Eye Disease</brief_title>
	<detailed_description>This Phase 3 , multi-center , double-masked , randomize , vehicle-controlled , parallel-group study design evaluate safety efficacy KPI-121 0.25 % ophthalmic suspension versus vehicle subject dry eye disease .</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>Have document clinical diagnosis dry eye disease eye Known hypersensitivity contraindication investigational product ( ) component History glaucoma , IOP &gt; 21 mmHg screen randomization visit , treat glaucoma either eye . Diagnosis : ongoing ocular infection ; severe/serious ocular condition judgment Investigator could confound study assessment limit compliance ; expose investigational drug within 30 day prior screen . In opinion Investigator study coordinator , unwilling unable comply study protocol unable successfully instill eye drop .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ocular Discomfort</keyword>
	<keyword>Pain</keyword>
	<keyword>Corticosteroid</keyword>
	<keyword>Hyperemia</keyword>
	<keyword>Dry Eye</keyword>
</DOC>